I agree unless they were able to portion out indic

I agree unless they were able to portion out indications under different names. The cancer drug is worth more than 21 billion alone. The only difference was that IMMU built a manufacturing facility. They got $88/share/21 billion total. The cost of the facility is unknown to me at this time but that would be deducted from final price.